Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients
Seminars in Arthritis and Rheumatism, Volume 48, No. 1, Year 2018
Notification
URL copied to clipboard!
Description
Objective: Interstitial lung disease (ILD) is one of the most serious complications of rheumatoid arthritis (RA). In the present study, we aimed to assess the efficacy of abatacept (ABA) in patients with ILD associated to RA. Methods: National multicenter, non-controlled, open-label registry study of RA patients with ILD treated with ABA. Results: 63 patients (36 women) with RA-associated ILD undergoing ABA therapy were studied. The mean ± standard deviation age at the time of the study was 63.2 ± 9.8 years. The median duration of RA and ILD from diagnosis were 6.8 and 1 year, respectively. RA was seropositive in 55 patients (87.3%). In 15 (23.8%) of 63 patients the development of ILD was closely related to the administration of synthetic or biologic disease modifying anti-rheumatic drugs. After a follow-up of 9.4 ± 3.2 months, two-thirds of patients remained stable whereas one-quarter experienced improvement in the Modified Medical Research Council scale. At that time forced vital capacity remained stable in almost two-thirds of patents and improved in one out of five patients assessed. Also, diffusing capacity of the lung for carbon monoxide remained stable in almost two-thirds and showed improvement in a quarter of the patients assessed. At 12 months, 50% of the 22 patients in whom chest HRCT scan was performed due persistence of respiratory symptoms showed stabilization, 8 (36.4%) improvement and 3 worsening of the HRCT scan pattern. Eleven of 63 patients had to discontinue ABA, mainly due to adverse events. Conclusion: ABA appears to be an effective in RA-associated ILD. © 2018 Elsevier Inc.
Authors & Co-Authors
Fernández-Díaz, Carlos
Spain, Santander
Universidad de Cantabria
Loricera, Javier
Spain, Santander
Universidad de Cantabria
Castañeda, Santos
Spain, Madrid
Hospital Universitario de la Princesa
López-Mejías, Raquel
Spain, Santander
Universidad de Cantabria
Carreira-Delgado, Patricia E.
Spain, Madrid
Hospital Universitario 12 de Octubre
Pérez Sandoval, Trinidad
Unknown Affiliation
Hernández-Cruz, Blanca E.
Spain, Sevilla
Hospital Universitario Virgen Macarena
Maíz Alonso, Olga
Spain, Donostia-san Sebastian
Osakidetza, Donostia University Hospital
Bonilla-Hernán, Gema
Spain, Madrid
Hospital Universitario la Paz
Blanco-Madrigal, Juan María
Spain, Bilbao
Osakidetza, Basurto University Hospital
Narváez, Javier A.
Spain, Barcelona
Hospital Universitari de Bellvitge
López-Corbeto, Mireia
Spain, Barcelona
Hospital Universitari Vall D'hebron
Romero-Yuste, Susana María
Spain, Pontevedra
Hospital de Pontevedra
González-Vela, María Carmen
Spain, Santander
Universidad de Cantabria
Mora-Cuesta, Victor Manuel
Spain, Santander
Universidad de Cantabria
Palmou, Natalia
Spain, Santander
Universidad de Cantabria
Herńandez, José L.
Spain, Santander
Universidad de Cantabria
González-Gay, Miguel Ángel
Spain, Santander
Universidad de Cantabria
Blanco-Alonso, Ricardo
Spain, Santander
Universidad de Cantabria
Statistics
Citations: 104
Authors: 19
Affiliations: 27
Identifiers
Doi:
10.1016/j.semarthrit.2017.12.012
ISSN:
00490172
Research Areas
Environmental
Study Design
Cohort Study
Participants Gender
Female